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Case Report
Diagnostic Genetics
A Case of Late-Onset Li-Fraumeni–like Syndrome with 
Unilateral Breast Cancer
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Li-Fraumeni syndrome (LFS) is a rare, inherited syndrome associated with increased risk 
of various early-onset tumors. Since the introduction of classic LFS criteria, various criteria 
have been proposed to include patients with incomplete LFS features, which make up Li-
Fraumeni-like syndromes (LFL). Germline missense mutations of TP53 are the primary 
cause of LFS and LFL. Mutations mostly reside in the DNA-binding domain of the gene 
and have a dominant-negative effect (DNE) over alternate wild-type alleles. Germline TP53 
mutation c.566C>T results in the missense mutation GCC (Ala) to GTC (Val) at codon 189 
(A189V) and has been reported in a case of multiple primary colon tumors. Herein we re-
port a second case of the same mutation in a breast cancer patient, who has familial his-
tory of late-onset malignancies. Due to the relatively late onset of malignancies, neither 
case fulfils previously defined criteria for the syndrome. Mutational analysis for breast tis-
sue in this patient showed a loss of heterozygosity. These clinical features may suggest a 
relatively weak DNE of A189V compared to other TP53 mutations, and in silico predictions 
and in vitro findings of the function of A189V mutant protein are conflicting. Considering 
the increased risk of malignancies and the therapeutic implications for patients who have 
a TP53 mutation, care must be taken when treating those who are suspected of possess-
ing cancer-prone traits due to TP53 mutation, especially when there is a family history of 
late-onset cancer with low penetrance.
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INTRODUCTION
Li-Fraumeni syndrome (LFS, OMIM #151623) is a rare, inherited 
syndrome with high penetrance, especially in women. It is asso-
ciated with increased risk of various early-onset tumors. Since 
the introduction of the syndrome in 1969 by Li and Fraumeni 
[1], various criteria have been developed to include those with 
incomplete LFS features, referred to as Li-Fraumeni–like syn-
dromes (LFL) [2-6].
 Tumor suppressor gene TP53 (chromosome 17p13.1; OMIM 
#191170) encodes the transcription factor p53, which plays a 
fundamental role in the tumor suppressor signaling pathway. 
The gene is activated in response to various types of cellular 
stresses, and p53 stops replication of stressed cells by binding 
to specific DNA sequences and transactivating genes [7]. Germ-
line mutations of TP53 are the primary cause of syndromes that 
include tendency to cancer, demonstrated in 70-80% of individ-
uals fulfilling classic LFS criteria and 20-40% of those fulfilling 
LFL criteria [8].
 Germline TP53 mutation c.566C>T causes a change from 
GCC (Ala) to GTC (Val) at codon 189 (A189V). This mutation was 
reported in a case of concurrent multiple primary colon tumors 
[9]. Although the patient was suspected to be prone to cancer, 
because of unusually late onset and absence of family history of 
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cancer, none of the clinical criteria for the syndrome was met. 
We report a case of a germline A189V mutation and discuss 
TP53 mutations with low penetrance. 
CASE REPORT
A 47-yr-old woman presented to a local hospital with a painless 
lump in the right breast that had been present for 1 month. She 
had no history of other breast complaints or surgeries. Her men-
arche occurred at age 14 yr and she gave birth to 3 children. 
There was no family history of breast or ovarian cancer, but 2 of 
her family members died from late-onset cancers (Fig. 1). On 
physical examination, a poorly defined, firm mass was noted in 
the medial upper portion of her right breast, measuring approxi-
mately 3 cm, and no axillary or cervical lymphadenopathy was 
detected. Mammography demonstrated a lesion highly suspi-
cious of cancer, and histological examination of the core needle 
biopsy of the lesion revealed invasive ductal carcinoma (IDC) of 
the breast. The patient was then transferred to our hospital for 
further evaluation and management of the cancer. Results for 
complete cell count, blood chemistry, and tumor markers (car-
cinoembryonic antigen; 0.8 ng/mL, cancer antigen 15-3; 5.3 U/
mL) were all within reference intervals. Screening for metastatic 
disease by computed tomography and positron emission tomog-
raphy showed no evidence of adjacent lymphatic, pulmonary, 
bone, or hepatic metastases.
 A pathologist reviewed slides from the other hospital and con-
firmed the diagnosis of IDC. The patient then underwent a par-
Fig. 1. Pedigree of the TP53 A189V family. Generations are in Roman numerals and individuals are in Arabic numbers (without parenthe-
sis). Individuals with a clinical diagnosis of a cancer are presented with a solid symbol and a footnote regarding the specific cancer type 
(age of onset). Individuals without a history of cancer are presented with open symbols. The proband is marked by an arrow.
Abbreviation: IDC, invasive ductal carcinoma.
Esophageal
cancer (61)
Lung cancer (70) IDC (47)
I
II
III
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Fig. 2. Nucleotide sequence analysis of the TP53 gene of family members. DNA-segments include the coding sequence 566 of the TP53 
gene (marked by black arrows). The patient had a compound heterozygous missense mutation in exon 6 (c.566C>T; p.Ala189Val) and 
IDC tissue was homozygous for the mutation. The patient’s 2 daughters (III-1 and III-2) were found to be heterozygous carriers for the mu-
tation, whereas the patient’s son (III-3) had a wild type TP53 gene.
Abbreviations: PB, peripheral blood; IDC, invasive ductal carcinoma.
Proband,
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Daughter 1 (III-1),
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c.566C>T (p.Ala189Val), Homozygote c.566C>T (p.Ala189Val), Heterozygote
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tial mastectomy of the right breast with ipsilateral, axillary senti-
nel lymph node biopsies. The final pathology of the tumor was 
IDC, and the cancer was staged as pT2N0M0. The specimen 
showed comedo-type necrosis with calcification and had a 
maximum diameter of 2.2 cm. The Nottingham classification 
[10] was II (moderately differentiated), and the total point score 
was 7 (2-3-2). The tumor cells stained positive for p53, and re-
sults for Ki67 were positive in 5% of the tumor cells. The carci-
noma displayed no nuclear reactivity for estrogen receptors, 
progesterone receptors, or HER-2. Biopsy findings for 7 sentinel 
lymph nodes were all negative. Although frozen sections, re-
moved during the surgery, were negative for malignancy, final 
pathology revealed malignant infiltrations in the deep layers of 
the inferior and medial margins. 
 Given the extensive family history of cancer, samples of pe-
ripheral blood (PB) lymphocytes and tumor tissue were as-
sessed for TP53 mutation. Briefly, DNA was extracted from 
breast cancer tissue and mononuclear cells from PB, and 5 to 9 
TP53 exons and intron-exon boundaries were studied. Analysis 
of PB revealed a germline heterozygotic A189V mutation that 
was homozygous in the IDC specimen (Fig. 2). Later, her 3 off-
springs underwent genetic screening, and 2 daughters (aged 20 
and 16 yr) were found to carry the mutation (Fig. 1 and 2) de-
spite absence of signs or symptoms of cancer. Patients (or their 
parents, if younger than 14 yr) gave informed consent for all 
molecular testing.
 After confirmation of the patient’s TP53 mutation status, an 
interdisciplinary panel met to determine the utility of localized 
radiotherapy, based on the suspected radiosensitivity of individ-
uals harboring a deleterious mutation in the TP53 gene [11, 12]. 
As partial mastectomy is generally followed by radiotherapy to 
increase the probability of tumor-free resection margins, risk of 
cancer relapse was determined to be greater than the risk of 
secondary carcinogenesis due to radiation. The patient has 
completed 4 cycles of adjuvant chemotherapy consisting of 
doxorubicin (60 mg, 32.8 mg/m2) and cyclophosphamide (500 
mg, 273.2 mg/m2), and 6,400 cGy of adjuvant radiotherapy is 
planned. The patient is currently well, without any signs or 
symptoms of cancer recurrence. 
DISCUSSION
Majority (75%) of TP53 mutations are missense substitutions 
[13]. Thus, understanding structure-function relationships is 
useful for comprehending the consequence of a TP53 mutation. 
The protein product p53 contains 393 amino acids constituting 
multiple functional domains. The core region (amino acids 96-
292) serves the most crucial functions as a DNA-binding do-
main (DBD), which recognizes cognate sequences in the regu-
latory region of the target gene [14]. Mutation in the DBD would 
disrupt DNA binding ability of p53, and for this reason, muta-
tions in the domain are assumed to be pathogenic. The Interna-
tional Agency for Research on Cancer (IARC) TP53 database 
(version R15, released in 2010, http://www-p53.iarc.fr/index.
html) [15] indicates that most germline missense mutations 
(1,394, or 79.4%) are also located in the DBD. Codon 189 re-
sides in the L2 loop motif of the DBD, which is necessary for the 
binding of p53 to the minor groove of the DNA. In silico assess-
ment of gene function, using both SIFT and Align-GVGD, pre-
dicted A189V to be deleterious [16]. However, experimental data 
in yeast demonstrated that the A189V mutant p53 retained fair 
transactivity compared with wild-type in vitro [17], complicating 
the prediction of its function in vivo.
 Genetic study of a well-designed control group is crucial to 
distinguish whether a missense nucleotide substitution is a poly-
morphism or a potentially deleterious mutation. Control subjects 
who are already past the mean age of onset are needed for ge-
netic studies of late-onset cancers [18]. Currently, there are no 
studies of TP53 in elderly Korean individuals who are confirmed 
to be cancer free and without any known family history of can-
cer. Yet, molecular tests for TP53 of 693 sporadic Korean breast 
cancer patients without family history of cancer (median age of 
49 yr, range 24-91 yr) found no case of A189V (unpublished 
data). 
 As p53 naturally binds DNA as a homotetramer, presence of 
a mutant protein interferes with a wild-type protein by forming 
hetero-oligomers, which might reduce transcriptional activity 
(dominant negative effect; DNE). Over 80% of mutated p53 are 
predicted to feature such an effect [13], in which case carcino-
genesis will begin early in life. In contrast, among mutations 
lacking a DNE, a single allelic mutation would not be sufficient 
to cause oncogenesis; alteration of another modifier gene would 
be necessary. Determination of loss of heterozygosity (LOH) sta-
tus within tumors has been reported to be important in carriers 
of a heterozygous TP53 mutation [19]. However, only a few p53 
mutants have been studied with respect to their DNE, and 
A189V has been studied in none. Given the lack of experimental 
data, clinical observations of time of disease onset and accom-
panying genetic alterations would be helpful in assessing the 
DNE of the mutant.
 The penetrance of TP53-mediated cancer is generally high, 
especially in women, because of breast cancer [8]. Patients with 
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typical LFS develop sarcomas at a young age, including breast 
cancers and brain tumors at less than 44 yr [20]. According to 
the IARC TP53 database, 13 somatic and 1 germline A189V mu-
tations have been identified. The previously reported case of a 
germline A189V mutation occurred in a patient with concurrent 
colon carcinomas at a late age without a familial history of can-
cer [9]. Somatic APC and/or KRAS mutations were found in all 
tumors, and, of note, the advanced carcinoma had an addi-
tional somatic mutation in the alternate TP53 allele (Table 1). In 
our case, the proband’s breast cancer developed at a relatively 
late age compared with other breast cancers in carriers having 
a TP53 mutation [20]. The patient’s father and half-brother both 
died from cancer that developed at a late age. However, the sig-
nificance of this is unknown, given the lack of information about 
their genotypes. Genetic information about the patient’s healthy 
siblings was not available. The patient’s breast IDC tissue also 
demonstrated LOH (Fig. 2), possibly because of loss of the alter-
nate allele. Segregational analysis was not possible because of 
incomplete genetic studies of family members; LOH in cancer 
tissues of the patient is the available evidence of pathogenicity. 
Also, clinical features of both cases of A189V mutation suggest 
that the DNE of A189V may be relatively weak compared with 
other, typical germline TP53 mutations.
 Li and Fraumeni first described LFS in 1969 based on retro-
spective analysis of families with soft tissue sarcomas during in-
fancy or childhood [1]. The spectrum of cancers typical of TP53 
mutations has been identified as breast cancer, sarcomas, brain 
tumors, adrenocortical carcinoma, and leukemia [21-23]. Stud-
ies in search of specific genotype-phenotype associations in 
subjects with TP53 mutation found a significant association be-
tween missense mutations in the L2 and L3 loops and brain tu-
mors [20]. Both A189V cases exhibited varied spectrums of 
cancers without a predilection for a certain type of cancer, and 
no brain tumors were found. With respect to breast cancer and 
the syndrome, a recent study revealed a significantly higher 
prevalence of HER2-positive tumors in subjects with the muta-
tion compared to those who did not have the mutation [24]. 
However, the breast IDC in our case tested negative for HER2.
 Radiotherapy has been demonstrated to play a small role in 
secondary carcinogenesis, with increasing doses of radiation for 
breast cancer treatment [11], and an even higher risk of devel-
oping radiation-induced malignancies was noted in breast can-
cer patients with germline TP53 mutations [12]. Yet, there are 
no generally accepted contraindications for any type of radia-
tion-based treatment or diagnostic modality. Physicians should 
assess the safety of radiotherapy with regard to possible benefits 
and risks. In our case, malignant cells were present in resection 
margins of the partial mastectomy specimen and the conclusion 
of interdisciplinary consultation was that local radiation therapy 
with adjuvant chemotherapy outweighed risks associated with 
the use of radiation. 
 The final issue we address is the clinical utility of diagnostic 
criteria for cancer-prone syndrome in carriers of TP53 germline 
mutations. Since the introduction of classic LFS criteria [1], 
supplementary LFL criteria have been suggested [2, 3]. Chom-
pret et al. [4-6] proposed modified criteria that demonstrated 
maximum clinical utility in combination with classic LFS [23]. 
However, approximately 4% of families harboring TP53 muta-
tions are missed with the current criteria [23]. Neither of the 
A189V cases fulfills any of the criteria, mainly because of the 
late onset of cancer and the lack of information about specific 
cancers in familial histories. As discussed here, certain TP53 
mutations lack a DNE, delaying clinical manifestations and re-
ducing disease penetrance. Carriers having such mutations 
Table 1. Germline TP53 mutation c.566C>T, p.Ala189Val from the literature review and the present case
No. case Sex/Age (yr) Cancer Accompanying somatic mutation Family history Reference
1 M/73 Advanced carcinoma of colon, NOS c.735G>A of TP53 No cancer [9]
c.1487_1488del of APC
c.4634C>G of APC
c.38G>A of KRAS
Early carcinoma of colon, NOS c.4132C>T of APC
c.35G>T of KRAS
Early carcinoma of colon, NOS c.1449_75dup of APC
Squamous cell carcinoma of the lung Unknown
2 F/47 Invasive ductal carcinoma of the breast Loss of alternate allele Esophageal cancer (father) present
Lung cancer (brother)
Abbreviations: M, male; F, female; NOS, not otherwise specified.
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may not be indicated for TP53 testing and miss the opportunity 
for cancer screening and optimal treatment. Thus, cancer-prone 
traits should be considered even in patients with late-onset can-
cers and low penetrance in their family, because TP53 mutation 
may be present despite absence of currently adopted LFS or 
LFL criteria. 
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